期刊
ATHEROSCLEROSIS
卷 359, 期 -, 页码 1-12出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2022.08.018
关键词
Gut microbiota; Cardiometabolic disease; Obesity; Hypercholesterolemia; Short chain fatty acids; Glucagon like peptide-1; Bile acids; Type II diabetes Mellitus; Statins; Metformin
资金
- German Federal Ministry of Education and Research (BMBF) [01ZX1906B]
- German Research Foundation (DFG) [HA 6951/2-1]
- Charite - Universitatsmedizin Berlin
- Berlin Institute of Health
The gut microbiota plays an important role in host metabolism and cardiometabolic disease, influencing lipid and glucose homeostasis through the metabolism of dietary nutrients and bioactive metabolites.
Accumulating evidence suggests an important role of gut microbiota in physiological processes of host metabolism as well as cardiometabolic disease. Recent advances in metagenomic and metabolomic research have led to discoveries of novel pathways in which intestinal microbial metabolism of dietary nutrients is linked to metabolic profiles and cardiovascular disease risk. A number of metaorganismal circuits have been identified by microbiota transplantation studies and experimental models using germ-free rodents. Many of these pathways involve gut microbiota-related bioactive metabolites that impact host metabolism, in particular lipid and glucose homeostasis, partly via specific host receptors.In this review, we summarize the current knowledge of how the gut microbiome can impact cardiometabolic phenotypes and provide an overview of recent advances of gut microbiome research.Finally, the potential of modulating intestinal microbiota composition and/or targeting microbiota-related pathways for novel preventive and therapeutic strategies in cardiometabolic and cardiovascular diseases will be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据